Chapter 1

CHRONIC PAIN PATIENTS AND QUALITY OF LIFE INSTRUMENTS – A SYSTEMATIC REVIEW

Liliane Mendonça¹, Luís Azevedo^{1,2}, & José Castro-Lopes^{1,3}

¹NOPain - National Observatory for Pain, Faculty of Medicine, University of Porto, Portugal ²CIDES - Department of Health Information and Decision Sciences, Faculty of Medicine, University of Porto, Portugal

³Department of Experimental Biology, Faculty of Medicine, University of Porto, Portugal

ABSTRACT

Background: Chronic pain is an overwhelmingly complex sensory and emotional experience that has a negative impact in health related quality of life (HRQoL). A meta-analysis was performed to quantitatively estimate HRQoL in chronic pain patients, based on SF-36 results. *Methods:* PubMed, PsycARTICLES, PsycINFO and EMBASE were searched. Query: "(chronic pain) (abstract) and ("quality of life" OR "HRQOL") (abstract)". Included studies should report HRQoL, using general HRQoL questionnaires, in adults with non-cancer chronic pain followed in pain management units. Studies methodological quality was evaluated using the QATSDD scale. The inverse variance method was employed to calculate pooled means and 95% CI for each dimension and subgroup analysis was performed. *Findings:* Electronic search retrieved 4608 articles, 35 were selected. These studies applied 11 HRQoL questionnaires, being SF-36 the most used (n=27, 77%). Pooled mean scores were low for every SF-36 dimension (ranging from 16 [10.06, 22.25], for Physical Role, to 52 [49.01, 54.63] for Mental Health, including summary scales: PCS 29.72 [28.12, 31.32] and MCS 42.89 [38.59, 47.19] (mean [95%CI]). *Discussion:* HRQoL of chronic pain patients is low in all dimensions. Psychological interventions have an important role to improve HRQoL in this population and should be promoted and encouraged.

Keywords: chronic pain, pain contexts, SF-36, meta-analysis.

1. INTRODUCTION

Chronic pain is a major challenge for medical community (Becker, Sjøgren, Bech, Olsen, & Eriksen, 2000), since it is an overwhelming complex sensory and emotional experience (Mazzola et al., 2009).

Today it is recognized that chronic pain has a negative impact on quality of life (QoL) (Borsbo, Peolsson, & Gerdle, 2009; Breivik et al., 2008; Lamé, Peters, Vlaeyen, Kleef, & Patijn, 2005; Tüzün, 2007). There are several QoL definitions, probably the most used is the World Health Organization's: QoL is "an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns" (Chandra & Ozturk, 2005). Some authors make a distinction between global concept of QoL (connected to broader aspects of Humanity) and health related quality of life (HRQoL). HRQoL measures treatment and disease process impact in the holistic aspects of a person's life, embracing emotional, social and physical development and their functional capacity in daily activities (Ferrer, 2002).

HRQoL physical, emotional and social dimensions have impact on chronic pain patient's pain exacerbation or relief (Ferrer, 2002). Even treatment outcomes are affected by cognitive, motivational and emotional factors (Mazzola et al., 2009).

Multidisciplinary pain treatment is probably the most effective for chronic pain patients (Becker et al., 2000), however, for several motives, not all chronic pain patients are treated in specialized pain centers. Valid HRQoL measures in pain units used systematically allow the identification of pain impact in patient's lives, selection of best treatment options, and outcome treatment evaluation (Ferrer, 2002). There is some consensus that individuals with chronic pain

Liliane Mendonça, Luís Azevedo, & José Castro-Lopes

and longer pain duration have lower HRQoL (Jamison, Fanciullo, McHugo, & Baird, 2007). Some studies about pain unit's patients indicate lower levels of HRQoL when compared with other chronic populations (Fredheim et al., 2008). However many of these studies use disease specific HROQoL questionnaires (e.g., Fibromyalgia Impact Questionnaire), or participants have very specific diagnoses (as cancer pain, fibromyalgia, neck pain, lumbar pain, pelvic pain or osteoarthritis) (Ferrer, 2002). SF-36 is the HRQoL questionnaire most widely used (Elliott, Renier, & Palcher, 2003) and over the years it has been refined and culturally adapted in several countries (Alonso et al., 2004; McDowell, 2006).

The SF-36 is a 36-item questionnaire, self-administered, applied in paper pencil or computer versions, that measures health-related functions in eight domains: physical functioning (PF), role limitations due to physical problems (RP), bodily pain (BP), vitality (VT), general health perceptions (GH), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). These eight dimensions scales are grouped into two health dimensions (summary scales): physical composite scale (PF, RP, BP, VT) and mental composite scale (SF, GH, RE, MH) (Jamison et al., 2007).

A systematic review was conducted to: 1) to identify HRQoL instruments used to evaluate chronic pain patients followed in pain management units; and 2) to quantitatively estimate HRQoL in non-cancer chronic pain patients, based on SF-36 outcomes, by performing a meta-analysis of studies estimating HRQoL in this population.

2. METHODS

2.1. Search strategy and inclusion criteria

Research was performed in several electronic databases: PubMed, EMBASE, SocINDEX, CINAHL, PsycARTICLES, PsycINFO and Cochrane Central Register of Controlled Trial and restricted to articles published until April 2011.

To conduct a sensitive search, query search was "(chronic pain) (title/abstract) and ("quality of life" OR "HRQOL") (title/abstract)" in PubMed. For all the others electronic databases query was "(chronic pain) (abstract) and ("quality of life" OR "HRQOL") (abstract)".

Inclusion criteria: a) all studies assessing HRQoL in adults (above 18 years) with chronic non cancer pain in pain contexts (pain clinics, pain management units or hospital pain specialized units) and with pain duration longer than 3 months; and b) studies describing HRQoL questionnaires application in chronic pain patients.

Exclusion criteria: a) articles assessing HRQoL in populations with specific pain diagnoses (e.g. cancer, fibromyalgia or osteoarthritis); b) studies focusing specific conditions in general diagnosis, as moderate to severe pain, intractable pain, or disabled patients by chronic pain; c) interventions that usually aren't first treatment choice, like ablative techniques; d) and, methodological studies as systematic reviews or case studies.

Inclusion process was carried out by one researcher on two occasions: first after reading title and abstract and then after reading full articles. All reasons of article's inclusion or exclusion were recorded and analyzed.

Article's collected information was: a) article's identification (title, author, publication year); b) study design, context, inclusion and exclusion criteria, sample size, pain diagnoses, pain duration, and applied questionnaires; c) and study participant's characteristics (mean age), HRQoL outcomes and predictors.

2.2. Statistical analysis

The inverse variance method was employed to calculate pooled means and confidence intervals (95%) for all SF-36 scales at baseline, since they are continuous variables, ranging from 0 to 100. The inverse variance method was also applied to aggregate information of several groups in the same study, which estimated pooled measures (mean, standard deviations and standard error) per study.

Random-effects model was used based on the assumption that estimated effects differ across studies, but follow the same distribution. Software used to aggregate data was Review Manager 5[®], which implements random-effects meta-analysis version described by DerSimonian and Laird (Deeks, Higgins, & Altman, 2011). Heterogeneity was explored through subgroup analyses considering study methodology, type of pain management unit, geographical region, participants mean age, and percentage of patients with low back pain.

Sensibility analysis for each SF-36 scale was performed removing one study at a time and then analyzing different pooled means. Publication bias was assessed by funnel plots for all SF-36 scales.

3. FINDINGS

After articles selection process 35 studies were included, see Figure 1.



Figure 1. Flowchart of literature search and review process.

Summary of the 35 included studies characteristics is presented in Table 1.

5

Authors	Type of study	HRQoL measure	Sample size	Age	Years with pain	Type or diagnosis of pain
Abbot et al. (2001), UK	Randomized Controlled Trials	SF-36	n=105; FH =25; SFH=25; DH=28; NH=27	FH - 53,6 (44,8- 58,8); SH - 48,9 (44,8-53,0); DH - 57,6 (53,5- 61,7); NH - 51,4 (48,1-54,7) ; M (95% CI)	FH - 10,9 (7,2- 14,6), SH - 11,7 (6,8-16,6); DH - 11,5 (7,2- 15,8); NH -10,0 (5,9-14,1); M (95% CI)	Trauma - 9; degenerative - 55; nerve damage - 22; miscellaneous - 5; unknown - 14
Adams (2002), USA	Cross- sectional	SF-36, QOLS	89	-	-	-
Becker et al. (2000), Denmark	Randomized Controlled Trials	SF-36	MPT=63; GP=63; WL=63	MPT - 57,7±15,8, GP- 55,1±14,6, WL- 57,2 ±15,5, M±SD	MPT- 10,2±9,1, GP-7,8±8,1, WL - 9,7±8,0, M±SD	Somatic - 73; neuropathic - 63; visceral - 17; psychogenic - 7; unknown - 7
Azevedo et al. (2007), Portugal	Validation study	SF-36	174	52,63 ±13,46, M±SD	-	Osteoarticular -47%; trauma – 3%; headache - 1%; surgical intervention - 11%; peripheral vascular disease - 3%; nervous system lesions - 8%; other – 28%
Caldwell, Hart-Johnson, & Green (2009), USA	Cross- sectional	SF-36	183; whites=92; blacks=91	38,2±7,5, M±SD	5±6,9, M±SD	Leg/foot - 62,7%; hip/pelvis - 53,8%; back pain - 55,6%
Cheung, Wong, Yap, & Chen (2008), China	Validation study	SF-36	224	41,8±10,3, M±SD	3,2±4,5, M±SD	Injuries at work - 59,4%; pain localization more than 3 sites - 33,5%, one site - 36,2%; back - 60,3%, neck - 11,6%, lower limbs - 8.9%, and other - 19,2%
Chibnall & Tait (1990), USA	Validation study	QOLS	393	42,4±12,8, M±SD	4,6±7,2, M±SD	Work accident - 46,6%; non-work accident - 18,8%; illness or surgery - 12%; no reason - 18,6%; unspecified events - 3,9%
Chibnall & Tait (1994), USA	Validation study	QOLS	765	-	-	-
Choinière et al. (2010), Canada	Longitudinal observational study	SF-36	728	50,8±12,6, M±SD	5 (0,5-55), Median (R)	Trauma - 308; surgery - 67; illness - 136; no precise event - 190; other - 27
Cusens, Duggan, Thorne, & Burch (2010), UK	Longitudinal intervention study	SF-36	IG=33; CG=20	IG - 46,7±11,5; CG - 48,4±12,3, M±SD	IG - 5,6±2,4; CG - 7,1±3,6, M±SD	Lower back pain: 24% and 45%; arthritis: 26% and 20%; sciatic injury: 18% and 10%; fibromyalgia: 18% and 10%, IG and CG respectively
Deshields, Tait, Gfeller, & Chibnall (1995), USA	Cross- sectional	QOLS	200	-	-	Low back, head/neck, and extremity pain
Elliott et al. (2003), USA	Cross- sectional	SF-36	242	46±0,8 (19–83), M±SD (R)	7,1±5,3, M±SD	Back pain - 57%; fibromyalgia/myofascial pain - 44%; neuropathic pain - 35%; headache - 25%; arthritis - 14%

Table 1. Summary of included studies characteristics.

Fredheim, Borchgrevink , Saltnes, & Kaasa (2007), Norway	Validation study	EORTC QLQ-C30, SF-36	286	45±13, M±SD	-	Generalized pain - 16%; neck pain - 15%; lumbar/thoracic pain - 19%,; localized musculoskeletal pain - 11%; neuropathic pain - 16%; somatoform pain disorders - 9%; other pain - 14%
Gerbershagen , Lindena, Korb, & Kramer (2002), Germany	Cross- sectional	NHP, SF- 36, German Life Satisfaction Scale	3294	51,3±14,8, M±SD	7,6±10,3, M±SD	Abdominal - 65; arm - 120; leg - 438; head/face - 853; back - 924; neck/shoulder - 245; fibromyalgia - 210; other - 439
Green & Hart-Johnson (2009), USA	Longitudinal intervention study	SF-36	182	-	-	-
Hart-Johnson & Green (2010), USA	Cross- sectional	SF-36	CP=49; NV: with chronic pain n=27 and without pain $n=28$	61-76 (R), older women	-	-
Jamison et al. (2007), USA	Validation study	WHOQOL- BREF, ICQOL-SF	\$1=300; \$2=336	S1 - 50,6±13,7; S2 - 51,5±14,5, M±SD	S1 - 8,7±2,0; S2 - 7,6±2,0; M±SD	Low back pain: S1 - 37%; S2 - 42,6%
Johnston, Foster, Shennan, Starkey, & Johnson (2010), New Zealand	Randomized Controlled Trials	Quality of Life Inventory	IG=12; CG=12	43 (20-84), M (R)	-	-
Kassardjian, Gardner-Nix, Dupak, Barbati, & Lam- McCullock (2008), Canada	Validation studies	SF-36, PRISM	Validation n=138; construt validity n=26	Validation - 50,5 (25–86); Construct validity - 48,6 (34–77), M (R)	>5 years: V - 131; CV - 24; <5 years: V - 7; CV - 2	Back pain: V - 67; CV - 14; fibromyalgia: V - 19; CV - 1; arthritis: V - 17; CV - 1; headache and facial: V - 6; CV - 2; other: V - 29; CV - 8
Kerr et al. (2004), Australia	Cross- sectional	SF-36	632	50±16 (20–93), M±SD (R)	-	Work accident - 23%, at work - 10%, at home - 8,5%; motor vehicle accident - 6%; surgery - 12,5%, illness - 2,5%; no reason - 23,5%; other - 11%
Kruis et al. (2009), Netherlands	Cross- sectional	SF-36	969	53±16, M±SD	5 (2-10), M (R)	-
Lamé et al. (2005), Netherlands	Cross- sectional	SF-36	1208	49,9±14,7, M±SD	-	Headache - 2.4%; neck pain and/or brachialgia - 23.3%; back pain and/or sciatica - 27.9%; other pain - 15.7%; multiple localisations - 30.1%
Lee et al. (2005), China	Cross- sectional	SF-36	166	45,2±13,5, M±SD	-	Work-related injury - 57; accident - 23; illness/surgery - 33; unknown - 42; other - 11
Man, Chu, Chen, Ma, & Gin (2007), China	Longitudinal intervention study	SF-36	45	42 (23-57), M (R)	4 (1-27,8), Median (R)	Back - 26; limbs - 10; neck - 3; chest - 2; multiple sites - 2; others - 2

Table 1. Summary of included studies characteristics (cont.).

Marcus (2003), USA	Cross- sectional	SF-36	H=110; HF= 385; HD=148	44,8, M	50% pain for longer than 5 years	Myofascial - 38.1%; mechanical - 18.0%; headache - 17.1%, radicular/neuropathic - 13.1%; fibromyalgia - 5.9%; other - 7.8%
Mazzola et al. (2009), Argentina	Longitudinal intervention study	SF-36	38	-	12, M	Headache - 30; fibromyalgia - 4; neuropathic pain - 4
Monsalve, Soriano, & De Andres (2006), Spain	Validation study	SF-36	112	50±12 (21 - 77), M±SD (R)	-	Neuropathic pain - 33,9%; somatic pain - 58%; visceral pain - 8,1%
Pecci (2007), Argentina	Cross- sectional	SF-36	CP=102; PD=208; MH=320	65±14,9, M±SD (Chronic pain)	-	-
Schofield (2002), UK	Longitudinal intervention study	Sickness Impact Profile	73	IG - 48,2 (32- 58); CG - 48,0 (29-65), M (R)	IG - 7,5; CG - 6,0, M	Low back pain - 60%
Schutze et al. (2009), Germany	Longitudinal intervention study	SF-36	189	49,3±10,4, M±SD	-	Back pain - 94; headache - 32; other pain - 63
Skevington, Carse, & De C. Williams (2001), UK	Validation studies	WHOQOL- 100, SF-36	106	44 (22–79), M (R)	8,1±8,6, M±SD	-
Tiberghien- Chatelain et al. (2008), France	Longitudinal intervention study	Quality-of- Life Visual Analog Scale	166	50±16, M±SD	7 (3); M (Median)	Rheumatologic - 33,1%; neuropathic - 28,9%; headache - 13,3%; complex regional pain syndrome - 12,7%; fibromyalgia - 4,8%; others - 7,6%
Torre et al. (2008), Spain	Longitudinal intervention study	SF-36	119	55,1±13,3, M±SD	7,9±10,6, M±SD	Back pain, osteoarticular pain, fibromyalgia, neuropathic pain and other
Vallerand (1998), USA	Validation study	City of Hope Quality of Life Survey	204	40,63±9,96, M±SD	2,7±4,5, M±SD	Pain origin: skeletal, neuropathic or soft tissue
Vranken et al. (2009), Netherlands	Cross- sectional	SF-36	388	-	-	-

Table 1. Summary of included studies characteristics (cont.).

M-Mean; 95% CI - 95% Confidence interval; SD-Standard deviation; R - Range

Eleven HRQoL questionnaires were used in these included studies, but SF-36 is by far the HRQoL questionnaire most applied to chronic pain patients (77%, n=27), regardless study methodology. Besides SF-36, the most frequent HRQoL questionnaires used are Quality of Life Scale (QOLS) (n=4, 11%) and WHOQOL questionnaires (WHOQOL-100 and WHOQOL-Bref, n=2, 6%). All the other HRQoL measures (City of hope Quality of Life Survey, EORTC QLQ-C30, ICQOL-SF, German Life Satisfaction Scale, Nottingham Health Profile, Quality of Life Inventory, Quality of Life Survey, Quality-of-Life Visual Analog Scale and Sickness Impact Profile) were applied in only one study.

There are several advantages of SF-36 use, namely: this is an instrument that has been applied in several populations, with strong reliability and validity and diverse country specific norms, has a survey manual and interpretation guide, is self-administered, can be used in personal or telephone interviews or by mail, and takes between 5 to 10 minutes to complete (Elliott et al., 2003; McDowell, 2006).

Of the 27 studies included with SF-36 outcomes, 16 (59%) studies had information available about SF-36 scales, 12 reported 8 dimension scale's mean and standard deviation (or other measures enabling standard error calculation) and 6 reported summary scales data

(2 studies reported dimension scales as well as summary scales). About the other 11 studies, 4 were abstracts and 7 described values like correlations or had graphic information.

3.1. Global quantitative results

Pooled estimates are low for every SF-36 dimension (ranging from 16 [10.06, 22.25], for the dimension Physical Role (Figure 2), to 52 [49.01, 54.63] for the dimension Mental Health (Figure 3) (mean [95%CI])). Scales associated with physical health tended to have lower values than those associated with mental health: Physical Function 25.72 [18.02, 33.42], Physical Role 16.29 [10.06, 22.25], Bodily Pain 25.56 [23.89, 27.23], Vitality 35.01 [32.72, 37.29], General Health 39.91 [37.13, 42.69], Social Functioning 46.43 [41.49, 51.37], Emotional Role 36.33 [26.61, 46.04] and Mental Health 52 [49.01, 54.63] (mean [95%CI]). This pattern was equally observed when pooling mean estimates of SF-36 summary scales: PCS 29.81 [27.32, 32.23] (Figure 4) and MCS 41.58 [38.91, 44.25] (mean [95%CI]) (Figure 5).

				Mean	Mean
Study or Subgroup	Mean	SE	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Abbot 2001	15.51	3.4	8.0%	15.51 [8.85, 22.17]	
Azevedo 2007	18.16	2.2	8.4%	18.16 [13.85, 22.47]	-
Becker 2000	17.41	2.5	8.3%	17.41 [12.51, 22.31]	-
Cheung 2008	8.1	1.6	8.6%	8.10 [4.96, 11.24]	-
Choinière 2010	26.23	0.9	8.7%	26.23 [24.47, 27.99]	•
Fredheim 2007	13	1.4	8.6%	13.00 [10.26, 15.74]	-
Gerbershagen 2002	23.2	0.6	8.7%	23.20 [22.02, 24.38]	-
Lame 2005	9.7	0.7	8.7%	9.70 [8.33, 11.07]	•
Lee 2005	10.4	1.8	8.5%	10.40 [6.87, 13.93]	+
Man 2007	0.58	0.6	8.7%	0.58 [-0.60, 1.76]	<u>†</u>
Mazzola 2009	29.97	5.5	6.9%	29.97 [19.19, 40.75]	
Torre Mollinedo 2008	26.88	3.7	7.8%	26.88 [19.63, 34.13]	
Total (95% CI)			100.0%	16.29 [10.06, 22.52]	•
Heterogeneity: Tau ² = 1	15.46; C	∶hi²=	998.29, d	f = 11 (P ≤ 0.00001); I ² =9	9%
Test for overall effect: Z	= 5.12 (P < 0	.00001)		0 50 100

Figure	2.	Role	ph	vsica	ıl.
			r · · ·		

				Mean	Mear	n	
Study or Subgroup	Mean	SE	Weight	IV, Random, 95% Cl	IV, Random,	, 95% Cl	
Abbot 2001	58.52	2.1	7.9%	58.52 [54.40, 62.64]		-	
Azevedo 2007	48	1.6	8.5%	48.00 [44.86, 51.14]		+	
Becker 2000	57.09	2	8.0%	57.09 [53.17, 61.01]		+	
Cheung 2008	40.9	1.3	8.8%	40.90 [38.35, 43.45]		+	
Choinière 2010	52.6	0.9	9.2%	52.60 [50.84, 54.36]		-	
Fredheim 2007	60	1.2	8.9%	60.00 [57.65, 62.35]		•	
Gerbershagen 2002	54.4	0.4	9.4%	54.40 [53.62, 55.18]			
Lame 2005	56.7	0.7	9.3%	56.70 [55.33, 58.07]		•	
Lee 2005	45.9	1.9	8.1%	45.90 [42.18, 49.62]		+	
Man 2007	45.8	2.9	6.8%	45.80 [40.12, 51.48]			
Mazzola 2009	47.16	2.5	7.4%	47.16 [42.26, 52.06]			
Torre Mollinedo 2008	52.78	2.3	7.6%	52.78 [48.27, 57.29]		+	
Total (95% CI)			100.0%	51.82 [49.01, 54.63]		•	
Heterogeneity: Tau ² = 2	4% 	<u> </u>					
Test for overall effect: Z = 36.17 (P < 0.00001)							

Figure 3. Mental health.

Figure 4. PCS.

				Mean	Me	ean	
Study or Subgroup	Mean	SE	Weight	IV, Random, 95% Cl	IV, Rando	m, 95% Cl	
Caldwell 2009	26.02	1.2	16.3%	26.02 [23.67, 28.37]		-	
Choinière 2010	29.83	0.3	19.1%	29.83 [29.24, 30.42]		•	
Elliott 2003	26.5	0.5	18.7%	26.50 [25.52, 27.48]		•	
Hart-Johnson 2010	28.91	2.81	9.7%	28.91 [23.40, 34.42]			
Schutze 2009	32.47	0.6	18.4%	32.47 [31.29, 33.65]		•	
Torre Mollinedo 2008	34.44	0.8	17.8%	34.44 [32.87, 36.01]		•	
Total (95% CI)			100.0%	29.81 [27.38, 32.23]		•	
Heterogeneity: Tau ² = 7 Test for overall effect: Z	(l D 50	100				

Figure 5. MCS.

				Mean	Mean	
Study or Subgroup	Mean	SE	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl	
Caldwell 2009	40.75	1.6	15.9%	40.75 [37.61, 43.89]		•
Choinière 2010	37.86	0.5	19.9%	37.86 [36.88, 38.84]	•	l -
Elliott 2003	40.44	0.9	18.8%	40.44 [38.68, 42.20]		•
Hart-Johnson 2010	50.27	3.12	9.8%	50.27 [44.15, 56.39]		-
Schutze 2009	44	0.9	18.8%	44.00 [42.24, 45.76]		•
Torre Mollinedo 2008	40.25	1.4	16.8%	40.25 [37.51, 42.99]	•	•
Total (95% CI)			100.0%	41.58 [38.91, 44.25]		•
Heterogeneity: Tau ² = 9	+	50 100				
Test for overall effect: Z	U	50 100				

Figure 6 is a graphic presentation of SF-36 dimensions estimates. Only Mental Health dimension has a mean estimate above 50, again SF-36 scales range between 0 and 100, where 100 represents the best HRQoL.



3.2. Subgroup analysis

All scales had high and significant heterogeneity. To explore moderators of heterogeneity different subgroup analysis were performed by type of study, type of pain management unit, geographical region, participants mean age, and percentage of patients with low back pain.

Considering subgroup analysis by type of study, across several designs differences were not statistically meaningful in most dimensions. In randomized controlled trials, participants tended to have higher scores, except for the Emotional Role dimension. On the other hand, participants in validation studies tended to have lower HRQoL scores. Differences were statistically significant in Physical Functioning (randomized controlled trials participants had higher values than observational and validation studies participants) and Mental Health scores (in intervention studies, randomized trials participants had higher values than longitudinal intervention studies participants).

Comparing summary scales, subjects in longitudinal intervention studies had significantly higher physical scores than participants of observational studies.

When analysing type of pain management unit, the only scale with significant differences between groups was the Mental Health dimension: patients in pain management clinics have lower Mental Health scores than patients in academic pain management centres and in tertiary multidisciplinary centres.

Dividing studies according to geographical region, only 3 continents are represented (America, Europe and Asia). Asian chronic pain patients had systematically lower HRQoL scores and differences were meaningful in Physical Functioning, Physical Role, Vitality, Emotional Role and Mental Health dimensions. Again, mean scores of Bodily Pain dimension of the 3 continents were very similar. Comparing Americans (North and South Americans) with Europeans, Americans tended to have significantly higher scores in Physical Role dimension, while Europeans tended to have significant higher values in Vitality and MCS dimensions.

SF-36 outcome comparison according to participant's mean age was also executed, when that information was available. In studies where participant's mean age was lower than 50 years SF-36 scores tended to be lower than in studies with participants mean age above 50 years. These differences are statistically meaningful in Physical Functioning and Vitality dimensions.

Another comparison performed between studies was based on percentage of low back pain patients in the sample. Considering studies where this information was available, studies with more low back pain patients (above 50% of the patients) had systematically lower HRQoL scores for all SF-36 dimensions. In General Health and MCS scores this difference was statistically significant.

Sensitivity analysis was performed first by removing each study and then considering studies mean quality assessment scale. Removing each study, SF-36 pooled scores remain very similar to the original pooling estimates.

In order to evaluate the risk of publication bias, a funnel plot was created for the pooled analysis of all SF-36 eight dimensions and for the two summary scales. Visual analysis of funnel plots did not detect major asymmetries. We concluded that in this case there was limited evidence of publication bias.

4. DISCUSSION

Regarding the identification of HRQoL instruments we concluded that the most frequently used questionnaire worldwide is the SF-36, however, we identified ten other questionnaires that have been used to measure this construct in this specific context. Besides SF-36, that has been extensively validated and is the most frequently used, other relevant questionnaires that deserve a special mention are:

a) The ICQOL-SF – developed specifically for pain patients, is adequately validated, short and easy to use;

b) The Quality of Life Scale – very short and easy to use and was developed specifically for pain patients;

c) The WHOQOL-BREF – generic, short and easy to use and adequately validated in several contexts;

d) Questionnaires specifically developed in cancer populations but have been also used in chronic pain patients with other disease aetiologies, like the EORTC QLQ-C30 and the City of Hope Quality of Life Survey; Liliane Mendonça, Luís Azevedo, & José Castro-Lopes

e) Other generic, classical and adequately validated HRQoL questionnaires, that are in general more comprehensive (large number of items and long times of completion), like the WHOQOL-100, the Sickness Impact Profile and the Nottingham Health Profile.

Quality of Life Scale and ICQOL-SF are pain specific HRQoL questionnaires, this indicates concern with chronic pain patient's HRQoL. There is a 10 years' time lag between these questionnaires development, probably items and dimensions increment, as well as complexity evolution reflect HRQOL concept's discussion.

It is possible to conclude based on the available evidence that the HRQoL levels of chronic pain patients are in general very low, lower than other chronic conditions and this is particularly true for physical health components of HRQoL. Although 27 studies applied SF-36 questionnaire, only in 16 studies scales outcomes were presented with mean values and standard deviations. Outcomes description and presentation changed according to study aims, and this complicated data aggregation. Even when mean scales and standard deviations were presented, sometimes researchers opted for presenting the 8 dimension scores, while others only presented summary scales and others present both set of scores.

Comparing our meta-analysis pooled estimates with IQOLA Project (Alonso et al., 2004), it is evident to conclude that chronic pain patients followed in pain management units have much lower HRQoL scores than general population and individuals with other chronic conditions (allergies, arthritis, chronic lung disease, congestive heart failure, diabetes, hypertension and ischemic heart disease). The IQOLA Project aggregates SF-36 results based in general population, which included subjects with chronic conditions, in 8 countries.

In subgroup analysis geographical region, age and low back pain are the best moderators of study heterogeneity. Among patients with chronic pain, Asians tend to have lower HRQoL values. We could think cultural conceptions would play a role in answers, but discrepancy with population norms is enormous (Lee et al., 2005), and SF-36 translations have cultural factors in consideration and good psychometric results in different countries. Regarding age, individuals bellow 50 years with chronic pain tend to perceive low HRQoL, and in this study, significant differences are mostly in physical dimensions (Physical Functioning and Vitality). This is consistent with literature probably because older people have pain for a longer time and developed better strategies to cope with pain and limitations in daily life are not seen as so problematic (Rustoen et al., 2005). Literature also supports the diminished HRQoL of low back pain patients (Lamé et al., 2005), usually associated with more functional limitations and catastrophizing thoughts about pain.

Sensitivity analysis conducted allowed to corroborate pooled estimates presented, since studies removal (one at the time) did not affect substantially the pooled estimates.

Although we have not found clear evidence of publication bias, it is always possible that this is a problem in the present study. There was an effort to include all articles regardless publication language (English, German, French, Spanish and Portuguese).

This study had some limitations that deserve further consideration. There are some limitations related to the systematic review process like the difficulty in specifying search terms or queries broad in scope. Thus the initial results of the literature search were quite extensive and it took an important amount of work and time to perform the studies selection phase.

After including only quantitative data from SF-36 applications, we found that an important part of the studies did not presented the adequate quantitative data needed to perform meta-analysis. We have contacted authors and made all efforts available in order to obtain these data.

The studies included in the meta-analysis presented high heterogeneity, associated with a high methodological variability and the existence of very different settings. Thus, we tried to assess the magnitude of the heterogeneity in every analysis performed and explored the sources of heterogeneity using sub-group analysis. However, in most cases the heterogeneity was significant and therefore pooled estimates presented should be analysed with caution.

The relevance of the present study is mainly associated with the presentation of meta-analytic estimates of HRQoL in non-cancer chronic pain patients followed in pain management units. To our knowledge, this is the first work presenting this kind of evidence for

this particular population. This work is an initial attempt to determine HRQoL of chronic pain patients in pain contexts. It would be interesting to evaluate changes in HRQoL during and after specialized pain treatment, enabling HRQoL changes monitorization and evaluate treatment impact of usual or specific treatments, like multidisciplinary treatment and the outcomes of psychological treatment.

REFERENCES

- Abbot, N. C., Harkness, E. F., Stevinson, C., Marshall, F. P., Conn, D. A., & Ernst, E. (2001). Spiritual healing as a therapy for chronic pain: A randomized, clinical trial. *Pain*, *91*(1), 79-89.
- Adams, N. J. (2002). Evaluating quality of life, functional capabilities, and coping strategies of people with chronic pain taking opioids versus no opioids. (Doctoral dissertation). Available from EBSCOhost rzh database.
- Alonso, J., Ferrer, M., Gandek, B., Ware, J. E., Aaronson, N. K., Mosconi, P., Rasmussen, N., Bullinger, M., Fukuhara, S., Kaasa, S., & Leplège, A. (2004). Health-related quality of life associated with chronic conditions in eight countries: Results from the International Quality of Life Assessment (IQOLA) Project. *Quality of Life Research*, 13(2), 283-298. doi:10.1023/b:qure.0000018472.46236.05
- Azevedo, L., Pereira, A., Dias, C., Agualusa, L., Lemos, L., Romão, J. & Castro-Lopes, J. (2007). Tradução, adaptação cultural e estudo multicêntrico de validação de instrumentos para rastreio e avaliação do impacto da dor crónica [Translation, cultural adaptation and multicenter validation of instruments for screening and evaluation of the impact of chronic pain]. *Dor*, 15(4), 6-58.
- Becker, N., Sjøgren, P., Bech, P., Olsen, A. K., & Eriksen, J. (2000). Treatment outcome of chronic non-malignant pain patients managed in a Danish multidisciplinary pain centre compared to general practice: A randomised controlled trial. *Pain*, 84(2), 203-211.
- Borsbo, B., Peolsson, M., & Gerdle, B. (2009). The complex interplay between pain intensity, depression, anxiety and catastrophising with respect to quality of life and disability. *Disability and Rehabilitation*, 31(19), 1605-1613.
- Breivik, H., Borchgrevink, P. C., Allen, S. M., Rosseland, L. A., Romundstad, L., Breivik Hals, E. K., Kvarstein, G., & Stubhaug, A. (2008). Assessment of pain. BJA: British Journal of Anaesthesia, 101(1), 17-24.
- Caldwell, J., Hart-Johnson, T., & Green, C. R. (2009). Body Mass Index and quality of life: Examining blacks and whites with chronic pain. *Journal of Pain*, *10*(1), 60-67.
- Chandra, A., & Ozturk, A. (2005). Quality of life issues and assessment tools as they relate to patients with chronic nonmalignant pain. *Hospital Topics*, 83(1), 33-37. doi:10.3200/htps.83.2.33-37
- Cheung, M. N., Wong, T. C., Yap, J. C., & Chen, P. P. (2008). Validation of the Chronic Pain Acceptance Questionnaire (CPAQ) in Cantonese-speaking Chinese patients. *Journal of Pain*, 9(9), 823-832. doi:10.1016/j.jpain.2008.04.005
- Chibnall, J. T., & Tait, R. C. (1990). The Quality of Life Scale: A preliminary study with chronic pain patients. *Psychology & Health*, 4(4), 283-292. doi:10.1080/08870449008400397
- Chibnall, J. T., & Tait, R. C. (1994). The short form of the Beck Depression Inventory: Validity issues with chronic pain patients. *Clinical Journal of Pain*, 10(4), 261-266.
- Choinière, M., Dion, D., Peng, P., Banner, R., Barton, P. M., Boulanger, A., Clark, A. J., Gordon, A. S., Guerriere, D. N., Guertin, M. C., Intrater, H. M., Lefort, S. M., Lynch, M. E., Moulin, D. E., Ong-Lam, M., Racine, M., Rashiq, S., Shir, Y., Taenzer, P., & Ware, M. (2010). The Canadian STOP-PAIN project Part 1: Who are the patients on the waitlists of multidisciplinary pain treatment facilities?. *Canadian Journal of Anaesthesia*, 57(6), 539-548. doi:10.1007/s12630-010-9305-5
- Cusens, B., Duggan, G. B., Thorne, K., & Burch, V. (2010). Evaluation of the breathworks mindfulness-based pain management programme: effects on well-being and multiple measures of mindfulness. *Clinical Psychology & Psychotherapy*, 17(1), 63-78. doi:10.1002/cpp.653
- Deeks, J. J., Higgins, J. P., & Altman, D. G. (2011). Chapter 9: Analysing data and undertaking meta-analyses (Part 2). In J. Higgins & S. Green (Eds.), *Cochrane handbook for systematic reviews of interventions* [Version 5.1.0, updated March 2011]. Retrieved from http://handbook.cochrane.org
- Deshields, T. L., Tait, R. C., Gfeller, J. D., & Chibnall, J. T. (1995). Relationship between social desirability and self-report in chronic pain patients. *Clinical Journal of Pain*, 11(3), 189-193.
- Elliott, T. E., Renier, C. M., & Palcher, J. A. (2003). Chronic pain, depression, and quality of life: Correlations and predictive value of the SF-36. *Pain Medicine*, 4(4), 331-339.

- Ferrer, M. (2002). *Calidad de vida como herramienta de control en las Unidades de dolor* [Quality of life as a control tool in Pain Units]. Paper presented at the V Congreso de la Sociedad Española del Dolor, Salamanca, Spain.
- Fredheim, O. M. S., Borchgrevink, P. C., Saltnes, T., & Kaasa, S. (2007). Validation and comparison of the health-related quality-of-life instruments EORTC QLQ-C30 and SF-36 in assessment of patients with chronic nonmalignant pain. *Journal of Pain & Symptom Management*, 34(6), 657-665.
- Fredheim, O. M. S., Kaasa, S., Fayers, P., Saltnes, T., Jordhøy, M., & Borchgrevink, P. C. (2008). Chronic non-malignant pain patients report as poor health-related quality of life as palliative cancer patients. Acta Anaesthesiologica Scandinavica, 52(1), 143-148. doi:10.1111/j.1399-6576.2007.01524.x
- Gerbershagen, H. U., Lindena, G., Korb, J., & Kramer, S. (2002). Gesundheitsbezogene Lebensqualität bei Patienten mit chronischen Schmerzen [Health-related quality of life in patients with chronic pain]. Der Schmerz, 16(4), 271-284. doi:10.1007/s00482-002-0164-z
- Green, C., & Hart-Johnson, T. (2009). A longitudinal examination of neighborhood socioeconomic factors and chronic pain outcomes. *Journal of Pain*, 10(4), S7.
- Hart-Johnson, T. A., & Green, C. R. (2010). Physical and psychosocial health in older women with chronic pain: comparing clusters of clinical and nonclinical samples. *Pain Medicine*, 11(4), 564-574. doi:10.1111/j.1526-4637.2010.00803.x
- Jamison, R. N., Fanciullo, G. J., McHugo, G. J., & Baird, J. C. (2007). Validation of the Short-Form Interactive Computerized Quality Of Life scale (ICQOL-SF). *Pain Medicine*, 8(3), 243-250.
- Johnston, M., Foster, M., Shennan, J., Starkey, N. J., & Johnson, A. (2010). The effectiveness of an acceptance and commitment therapy self-help intervention for chronic pain. *Clinical Journal of Pain*, 26(5), 393-402.
- Kassardjian, C. D., Gardner-Nix, J., Dupak, K., Barbati, J., & Lam-McCullock, J. (2008). Validating PRISM (Pictorial Representation of Illness and Self Measure) as a measure of suffering in chronic non-cancer pain patients. *Journal of Pain*, 9(12), 1135-1143.
- Kerr, S., Fairbrother, G., Crawford, M., Hogg, M., Fairbrother, D., & Khor, K. E. (2004). Patient characteristics and quality of life among a sample of Australian chronic pain clinic attendees. *Internal Medicine Journal*, 34(7), 403-409. doi:10.1111/j.1444-0903.2004.00627.x
- Kruis, R., Dijkgraaf, M., Van Der Vegt, M., Wegener, J., Renshof, S., De Klerk, M., & Vranken, J. (2009). Pain epidemiology and quality of life in chronic nonmalignant pain patients referred to a Dutch academic multidisciplinary pain center. *European Journal of Pain*, 13, S231.
- Lamé, I. E., Peters, M. L., Vlaeyen, J. W. S., Kleef, M. V., & Patijn, J. (2005). Quality of life in chronic pain is more associated with beliefs about pain, than with pain intensity. *European Journal Of Pain*, 9(1), 15-24.
- Lee, S., Chen, P. P., Lee, A., Ma, M., Wong, C. M., & Gin, T. (2005). A prospective evaluation of health-related quality of life in Hong Kong chinese patients with chronic non-cancer pain. *Hong Kong Medical Journal*, 11(3), 174-180.
- Man, A. K. Y., Chu, M. C., Chen, P. P., Ma, M., & Gin, T. (2007). Clinical experience with a chronic pain management programme in Hong Kong Chinese patients. *Hong Kong Medical Journal*, 13(5), 372-378.
- Marcus, D. A. (2003). Headache and other types of chronic pain. *Headache: The Journal of Head & Face Pain, 43*(1), 49-53.
- Mazzola, A., Calcagno, M. L., Goicochea, M. T., Pueyrredòn, H., Leston, J., & Salvat, F. (2009). EMDR in the Treatment of Chronic Pain. *Journal of EMDR Practice and Research*, 3(2), 66-79. doi:10.1891/1933-3196.3.2.66
- McDowell, I. (2006). General health status and quality of life. In I. McDowell (Ed.), *Measuring health* A guide to rating scales and questionnaires (3rd ed., pp. 520-702). New York, NY: Oxford University Press.
- Monsalve, V., Soriano, J., & De Andres, J. (2006). The LATTINEN INDEX (IL) for the evaluation of chronic pain: Its correlation with coping and quality of life. *Revista de la Sociedad Espanola del Dolor*, 13(4), 216-229.
- Pecci, C. (2007). Chronic disease and quality of life. Vertex, 18(72), 111-119.
- Schofield, P. (2002). Evaluating Snoezelen for relaxation within chronic pain management. British Journal of Nursing, 11(12), 812-821.
- Rustoen, T., Wahl, A. K., Hanestad, B. R., Lerdal, A., Paul, S., & Miaskowski, C. (2005). Age and the experience of chronic pain: Differences in health and quality of life among younger, middle-aged, and older adults. *Clinical Journal of Pain*, 21(6), 513-523.

- Schutze, A., Kaiser, U., Ettrich, U., Grosse, K., Gossrau, G., Schiller, M., Pöhlmann, K., Brannasch, K., Scharnagel, R., & Sabatowski, R. (2009). Evaluation einer multimodalen Schmerztherapie am UniversitätsSchmerzCentrum Dresden [Evaluation of a multimodal pain therapy at the university pain centre Dresden]. *Der Schmerz*, 23(6), 609-617.
- Skevington, S. M., Carse, M. S., & De C. Williams, A. C. (2001). Validation of the WHOQOL-100: Pain management improves quality of life for chronic pain patients. *Clinical Journal of Pain*, 17(3), 264-275.
- Tiberghien-Chatelain, F., Havet, C., Piccand, V., Balp, L., Dovico, C., Delacour, J. L., Girod, A., Fontaine, P., Lajoie, J. L. & Lallier, E. (2008). Comment un réseau douleur régional peut-il améliorer la prise en charge des patients atteints de douleur chronique? Discussion à partir des résultats d'une étude réalisée chez 166 patients pris en charge dans les structures douleur de Franche-Comté [How can a regional pain center improve management practices for patients with chronic pain? Discussion on a study of 166 patients attending Franche-Comte pain clinics]. Douleurs, 9(3), 118-126.
- Torre, F., Martin-Corral, J., Callejo, A., Gomez-Vega, C., La Torre, S., Esteban, I. & Arizaga, A. (2008). Health-related quality of life and coping strategies with regard to pain, in patients attended in a unit of pain. *Revista de la Sociedad Espanola del Dolor*, 15(2), 83-93.
- Tüzün, E. H. (2007). Quality of life in chronic musculoskeletal pain. *Best Practice & Research Clinical Rheumatology*, 21(3), 567-579. doi:10.1016/j.berh.2007.03.001
- Vallerand, A. H. (1998). Development and testing of the inventory of functional status-chronic pain. Journal of Pain and Symptom Management, 15(2), 125-133.
- Vranken, J., Van Der Vegt, M. H., Scholten, E. H., Van Beek, R., Miedema, D., & Hollmann, M. (2009). The impact of neuropathic pain on quality of life in patients with chronic nonmalignant pain. *Pain Practice*, 9, 44.

AUTHOR(S) INFORMATION

Full name: Liliane Vélia Ferreira Mendonça

Institutional affiliation: National Observatory for Pain - NOPain, Faculty of Medicine, University of Porto

Institutional address: Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal

Biographical sketch: MSc in Health Evidence and Decision at the Faculty of Medicine of the University of Porto (FMUP). Has a Post Graduation in Health Psychology and the graduation in Psychology at University of Minho. Works as a research assistant in the area of chronic pain in National Observatory for Pain - NOPain.

Full name: Luís Filipe Ribeiro Azevedo

Institutional affiliation: National Observatory for Pain - NOPain, Faculty of Medicine, University of Porto; CIDES - Department of Health Information and Decision Sciences, Faculty of Medicine, University of Porto

Institutional address: Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal

Biographical sketch: Luis Filipe Azevedo, MD PhD, is a Professor and Principal Investigator at the Faculty of Medicine of the University of Porto (FMUP) and at the Centre for Research in Health Services and Technologies (CINTESIS). He graduated as a Medical Doctor in 2001 at FMUP. He obtained a Post Graduate Specialty Diploma in Probability and Statistics at the University of Lisbon (2006-2007). He completed with honours his PhD in Clinical and Health Services Research at FMUP in 2013. He is member of the Board of the National Observatory for Pain – NOPain, since 2008. He is consultant of the Portuguese Northern Pharmacosurveillance Unit, since 2001. He was member and consultant of the Pharmacy and Therapeutics Committee of the Portuguese Northern Regional Health Administration (2005-2011). He has been involved in more than 12 research projects and he is author of 55 full text papers published in international scientific journals (https://www.researchgate.net/profile/Luis_Azevedo).

Full name: José Manuel Pereira Dias de Castro Lopes

Institutional affiliation: National Observatory for Pain - NOPain, Faculty of Medicine, University of Porto; Department of Experimental Biology, Faculty of Medicine, University of Porto **Institutional address:** Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal Liliane Mendonça, Luís Azevedo, & José Castro-Lopes

Biographical sketch: José M. Castro-Lopes is full professor of Histology and Embryology, chair of Pain Medicine and head of the Department of Experimental Biology of the Faculty of Medicine of the University of Porto (FMUP), where he is also director of the Post-Graduate Course on Pain Medicine. He received his MD and PhD at the FMUP and worked in the Max-Planck Institute for Psychiatry in Munich, the School of Pharmacy in London and the Unit 161 of the INSERM in Paris. The neurobiology of pain is the main research field of Prof. Castro-Lopes, in particular the changes induced in the Central Nervous System by chronic pain, and he has published many articles and some books, book chapters and review articles on that subject. More recently, Prof. Castro-Lopes coordinates a research group focusing on the epidemiology of pain in Portugal and he is the President of the National Observatory for Pain - NOPain.